Literature DB >> 2226500

In vitro susceptibility of Helicobacter pylori to the new oral cephalosporins cefpodoxime, ceftibuten and cefixime.

T U Westblom1, S Gudipati, B R Midkiff.   

Abstract

The in vitro activity against 30 Helicobacter pylori strains of three new third generation cephalosporins, cefpodoxime, ceftibuten and cefixime, which can be administered orally, was determined using an agar dilution technique under microaerophilic conditions. The MIC50 and MIC90 of cefpodoxime was 0.5 and 4.0 micrograms/ml respectively, of ceftibuten 2.0 and 8.0 micrograms/ml, and of cefixime 0.06 and 0.5 microgram/ml. All antibiotics showed good activity against Helicobacter pylori, cefixime having the highest activity of the three agents.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2226500     DOI: 10.1007/bf01964274

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  11 in total

1.  In vitro activities of new oral beta-lactams and macrolides against Campylobacter pylori.

Authors:  J A García-Rodríguez; J E García Sánchez; M I García García; E García Sánchez; J L Muñoz Bellido
Journal:  Antimicrob Agents Chemother       Date:  1989-09       Impact factor: 5.191

Review 2.  Chronic gastritis--a pathogenetic approach.

Authors:  J I Wyatt; M F Dixon
Journal:  J Pathol       Date:  1988-02       Impact factor: 7.996

Review 3.  Duodenal ulcer, Campylobacter pylori, and the "leaking roof" concept.

Authors:  C S Goodwin
Journal:  Lancet       Date:  1988 Dec 24-31       Impact factor: 79.321

4.  Antimicrobial activity, spectrum, and recommendations for disk diffusion susceptibility testing of ceftibuten (7432-S; SCH 39720), a new orally administered cephalosporin.

Authors:  R N Jones; A L Barry
Journal:  Antimicrob Agents Chemother       Date:  1988-10       Impact factor: 5.191

5.  Antibacterial activities of cefpodoxime, cefixime, and ceftriaxone.

Authors:  C C Knapp; J Sierra-Madero; J A Washington
Journal:  Antimicrob Agents Chemother       Date:  1988-12       Impact factor: 5.191

6.  Activity of cefixime (FK 027) for resistant gram-negative bacilli.

Authors:  S M Smith; R H Eng
Journal:  Chemotherapy       Date:  1988       Impact factor: 2.544

7.  Guinea pig model for antibiotic transport across gastric mucosa: inhibitory tissue concentrations of clindamycin against Helicobacter pylori (Campylobacter pylori) following two separate dose regimens.

Authors:  T U Westblom; D E Duriex; E Madan; R B Belshe
Journal:  Antimicrob Agents Chemother       Date:  1990-01       Impact factor: 5.191

Review 8.  Campylobacter pylori--therapy review.

Authors:  A T Axon
Journal:  Scand J Gastroenterol Suppl       Date:  1989

9.  Recurrence of duodenal ulcer and Campylobacter pylori infection after eradication.

Authors:  T J Borody; P Cole; S Noonan; A Morgan; J Lenne; L Hyland; S Brandl; E G Borody; L L George
Journal:  Med J Aust       Date:  1989-10-16       Impact factor: 7.738

10.  Cefixime: spectrum of antibacterial activity against 16,016 clinical isolates.

Authors:  A L Barry; R N Jones
Journal:  Pediatr Infect Dis J       Date:  1987-10       Impact factor: 2.129

View more
  8 in total

Review 1.  Clinical and economic considerations in the use of third-generation oral cephalosporins.

Authors:  S T Chambers; D R Murdoch; M J Pearce
Journal:  Pharmacoeconomics       Date:  1995-05       Impact factor: 4.981

2.  Antibacterial properties of lansoprazole alone and in combination with antimicrobial agents against Helicobacter pylori.

Authors:  M Nakao; M Tada; K Tsuchimori; M Uekata
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1995-05       Impact factor: 3.267

Review 3.  A risk-benefit assessment of drugs used in the eradication of Helicobacter pylori infection.

Authors:  A Hackelsberger; P Malfertheiner
Journal:  Drug Saf       Date:  1996-07       Impact factor: 5.606

Review 4.  Ceftibuten pharmacokinetics and pharmacodynamics. Focus on paediatric use.

Authors:  G L Kearns; R A Young
Journal:  Clin Pharmacokinet       Date:  1994-03       Impact factor: 6.447

5.  In vitro susceptibility of Helicobacter pylori to trospectomycin, pirlimycin (U-57930E), mirincamycin (U-24729A) and N-demethyl clindamycin (U-26767A).

Authors:  T U Westblom; B R Midkiff; S J Czinn
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1993-07       Impact factor: 3.267

6.  Helicobacter pylori infection in a pediatric population: in vitro susceptibilities to omeprazole and eight antimicrobial agents.

Authors:  V G Loo; P Sherman; A G Matlow
Journal:  Antimicrob Agents Chemother       Date:  1992-05       Impact factor: 5.191

Review 7.  Cefpodoxime proxetil. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential.

Authors:  J E Frampton; R N Brogden; H D Langtry; M M Buckley
Journal:  Drugs       Date:  1992-11       Impact factor: 9.546

Review 8.  Ceftibuten. A review of its antibacterial activity, pharmacokinetic properties and clinical efficacy.

Authors:  L R Wiseman; J A Balfour
Journal:  Drugs       Date:  1994-05       Impact factor: 9.546

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.